This company listing is no longer active
Yourgene Health Dividends and Buybacks
Dividend criteria checks 0/6
Yourgene Health does not have a record of paying a dividend.
Key information
n/a
Dividend yield
0.006%
Buyback Yield
| Total Shareholder Yield | 0.006% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Yourgene Health Plc (LON:YGEN) Shares Could Be 34% Above Their Intrinsic Value Estimate
Sep 22
Is There An Opportunity With Yourgene Health Plc's (LON:YGEN) 35% Undervaluation?
Apr 15We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Yourgene Health Plc's (LON:YGEN) CEO For Now
Sep 22Estimating The Intrinsic Value Of Yourgene Health Plc (LON:YGEN)
Aug 07Does This Valuation Of Yourgene Health Plc (LON:YGEN) Imply Investors Are Overpaying?
Feb 25What Did Yourgene Health's (LON:YGEN) CEO Take Home Last Year?
Jan 27What Kind Of Shareholders Hold The Majority In Yourgene Health Plc's (LON:YGEN) Shares?
Dec 22Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if YGEN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if YGEN's dividend payments have been increasing.
Dividend Yield vs Market
| Yourgene Health Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (YGEN) | n/a |
| Market Bottom 25% (GB) | 2.1% |
| Market Top 25% (GB) | 5.9% |
| Industry Average (Medical Equipment) | 2.6% |
| Analyst forecast (YGEN) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate YGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate YGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as YGEN has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/09/08 03:19 |
| End of Day Share Price | 2023/09/08 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2022/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Yourgene Health Plc is covered by 6 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Cavendish |
| Mark Brewer | Cavendish |
| Martin Hall | Hardman & Co. |